We are live on ! Find out more
TCM

Tekla Capital Management Portfolio holdings

AUM $2.56B
1-Year Est. Return 18.15%
This Fund
S&P 500
This Quarter Est. Return
+13.64%
1 Year Est. Return
+18.15%
3 Year Est. Return
+62.51%
5 Year Est. Return
+140.53%
10 Year Est. Return
+502.91%
AUM
$2.46B
AUM Growth
+$126M
Cap. Flow
-$103M
Cap. Flow %
-4.19%
Top 10 Hldgs %
40.31%
Holding
211
New
10
Increased
47
Reduced
69
Closed
17

Top Buys

Rank Stock Value
1
PFE icon
Pfizer
PFE
+$23.4M
2
MRK icon
Merck
MRK
+$20M
3
WELL icon
Welltower
WELL
+$14.4M
4
CI icon
Cigna
CI
+$9.62M
5
LLY icon
Eli Lilly
LLY
+$9.59M

Top Sells

Rank Stock Value
1
BIIB icon
Biogen
BIIB
+$25.4M
2
JNJ icon
Johnson & Johnson
JNJ
+$18M
3
ALXN
Alexion Pharmaceuticals
ALXN
+$15M
4
ABBV icon
AbbVie
ABBV
+$14.1M
5
VTRS icon
Viatris
VTRS
+$13.4M

Sector Composition

Rank Sector Weight
1 Healthcare 94.43%
2 Real Estate 2.93%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
XNCR icon
126
Xencor
XNCR
$1.5B
$2.25M 0.09%
72,382
+16,210
+29% +$539K
PTGX icon
127
Protagonist Therapeutics
PTGX
$8.79B
$2.23M 0.09%
177,425
-19,713
-10% -$174K
HR
128
DELISTED
Healthcare Realty Trust Incorporated
HR
$2.18M 0.09%
68,000
– –
IOVA icon
129
Iovance Biotherapeutics
IOVA
$1.82B
$2.06M 0.08%
216,908
– –
BOLD
130
DELISTED
Audentes Therapeutics, Inc
BOLD
$2.05M 0.08%
52,574
– –
MYOK
131
DELISTED
MyoKardia, Inc. Common Stock
MYOK
$2.01M 0.08%
38,600
– –
TFX icon
132
Teleflex
TFX
$6.05B
$1.93M 0.08%
6,379
– –
EDIT icon
133
Editas Medicine
EDIT
$396M
$1.88M 0.08%
76,668
– –
CLVS
134
DELISTED
Clovis Oncology, Inc.
CLVS
$1.87M 0.08%
75,400
– –
GHDX
135
DELISTED
Genomic Health, Inc.
GHDX
$1.86M 0.08%
26,531
+9,161
+53% +$679K
ARDX icon
136
Ardelyx
ARDX
$1.22B
$1.79M 0.07%
639,370
– –
AKBA icon
137
Akebia Therapeutics
AKBA
$354M
$1.75M 0.07%
213,942
– –
VRNA
138
DELISTED
Verona Pharma
VRNA
$1.72M 0.07%
275,000
– –
MDGL icon
139
Madrigal Pharmaceuticals
MDGL
$10.8B
$1.67M 0.07%
13,340
+6,670
+100% +$829K
CRL icon
140
Charles River Laboratories
CRL
$11.2B
$1.54M 0.06%
10,640
-12,030
-53% -$1.58M
SYNH
141
DELISTED
Syneos Health, Inc. Class A Common Stock
SYNH
$1.5M 0.06%
+29,027
New +$1.41M
MASI
142
DELISTED
Masimo
MASI
$1.48M 0.06%
10,715
-6,296
-37% -$790K
SNR
143
DELISTED
NEW SENIOR INVESTMENT GROUP INC.
SNR
$1.44M 0.06%
263,647
-51,100
-16% -$261K
DOC icon
144
Healthpeak Properties
DOC
$15.1B
$1.42M 0.06%
45,500
– –
MRNS
145
DELISTED
Marinus Pharmaceuticals, Inc
MRNS
$1.37M 0.06%
82,109
-106,835
-57% -$1.54M
ITCI
146
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$1.34M 0.05%
110,193
– –
HR icon
147
Healthcare Realty
HR
$7.28B
$1.31M 0.05%
46,000
– –
DPLO
148
DELISTED
DIPLOMAT PHARMACY, INC.
DPLO
$1.25M 0.05%
214,845
-290,856
-58% -$3M
SPPI
149
DELISTED
Spectrum Pharmaceuticals Inc
SPPI
$1.23M 0.05%
114,670
– –
ARQL
150
DELISTED
Arqule Inc
ARQL
$1.2M 0.05%
250,000
– –
4 5
6
7 8

Similar funds

EST
EA Series Trust Havertown, Pennsylvania $2.84B AUM
VIA
Vident Investment Advisory Alpharetta, Georgia $2.9B AUM 24.67% 1-Year Est. Return
AWS
AJ Wealth Strategies New York $2.07B AUM 10.86% 1-Year Est. Return
JP
Jana Partners New York $1.34B AUM 4.95% 1-Year Est. Return
VCM
Vigilant Capital Management Portland, Maine $1.34B AUM 15.33% 1-Year Est. Return
FCFS
First Command Financial Services Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
FCB
First Command Bank Fort Worth, Texas $1.06B AUM 10.74% 1-Year Est. Return
BWM
BerganKDV Wealth Management Bloomington, Minnesota $1,000M AUM 9.95% 1-Year Est. Return

Tekla Capital Management's Q1 2019 Portfolio in Review

As of Q1 2019, Tekla Capital Management held 211 positions worth $2.46B, up 5.4% from $2.34B the previous quarter. Its ten largest holdings account for 40% of the portfolio.

Tekla Capital Management withdrew a net $103M in Q1 2019, closing 17 positions and reducing 69 holdings. Its most notable exit was Shire pic, an estimated $6.3M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 94% of assets, up from 94% a quarter earlier, followed by Real Estate.

Against the trend, Tekla Capital Management opened a new position in Bio-Techne worth $4.31M.

  • Tekla Capital Management's largest Q1 2019 buy was Bio-Techne: 86,804 shares worth $4.31M.
  • Tekla Capital Management added most to Pfizer in Q1 2019, an estimated $23.4M increase.
  • Tekla Capital Management's biggest Q1 2019 reduction was Biogen, cutting an estimated $25.4M.
  • Tekla Capital Management fully exited Shire pic in Q1 2019, selling an estimated $6.3M.
  • Tekla Capital Management's ten largest holdings make up 40% of its $2.46B portfolio in Q1 2019.
  • Tekla Capital Management opened 10 new positions and closed 17 in Q1 2019.
  • Tekla Capital Management's portfolio value rose 5.4% quarter-over-quarter to $2.46B.

Based on Tekla Capital Management's 13F filing for Q1 2019, filed 14 May 2019.